---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-007835"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:36:30.850103+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CytomX Q1 2022 revenue $17.1M; cash $263M; pipeline data expected H2 2022

## Summary
- Cash, equivalents and investments $263M at March 31, 2022, down from $305M at Dec 31, 2021.
- Total revenue $17.1M for Q1 2022, up from $16.0M in Q1 2021, primarily from AbbVie collaboration.
- R&D expenses $30.6M (up $8.2M YoY); G&A $10.5M (up $1.3M YoY); operating loss implied.
- Phase 2 praluzatamab ravtansine: Arm A enrollment complete; initial data for Arms A & B in H2 2022.
- CX-2029 completed enrollment in squamous NSCLC cohort; data update expected in H2 2022.

## SEC filing metadata
- accession: 0000950170-22-007835
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017022007835/0000950170-22-007835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017022007835/ctmx-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-007835
- JSON: https://secwatch.observer/filing/0000950170-22-007835.json
- Plain text: https://secwatch.observer/filing/0000950170-22-007835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.